Interferon Beta-1b
- Atc Codes:L03AB08
- CAS Codes:145155-23-3
- PHARMGKB ID:145155-23-3
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Betaferon; Belgium: Betaferon, Extavia; Bulgaria: Betaferon, Extavia; Cyprus: Betaferon; Czech Republic: Betaferon, Extavia; Denmark: Betaferon, Extavia; Estonia: Betaferon, Extavia; Finland: Betaferon, Extavia; France: Betaferon, Extavia; Germany: Betaferon, Extavia; Greece: Betaferon, Extavia; Hungary: Betaferon, Extavia; Ireland: Betaferon, Extavia; Italy: Betaferon, Extavia; Latvia: Betaferon, Extavia; Lithuania: Betaferon, Extavia; Luxembourg: Betaferon, Extavia; Malta: Betaferon, Extavia; Netherlands: Betaferon, Extavia; Poland: Betaferon, Extavia; Portugal: Betaferon, Extavia; Romania: Betaferon, Extavia; Slovakia: Betaferon, Extavia; Slovenia: Betaferon, Extavia; Spain: Betaferon, Extavia; Sweden: Betaferon, Extavia; UK: Betaferon, Extavia.
North America
Canada: Betaseron; USA: Betaseron, Extavia.
Latin America
Argentina: Betaferon; Brazil: Betaferon; Mexico: Betaferon.
Asia
Japan: Betaferon.
Drug combinations
Chemistry
Interferon Beta-1b: C~903~H~1399~N~245~O~252~S~5~. Mw: 19,879.60. Interferon beta-1b is a non-glycosylated polypeptide produced in E. coli and consisting of 165 aa residues. 2-166-Interferon β~1~ (human fibroblast reduced), 17-L-serine-. CAS-145155-23-3 (1994).
Pharmacologic Category
Biologic Response Modifiers. (ATC-Code: L03AB08).
Mechanism of action
Mechanism in treatment of multiple sclerosis unknown. However, immunomodulatory effects include enhancement of suppressor T cell activity, reduction of proinflammatory cytokines, down-regulation of antigen presentation, and reduced trafficking of lymphocytes into CNS.
Therapeutic use
Treatment of relapsing forms of multiple sclerosis.
Pregnancy and lactiation implications
Abortifacient activity reported in Rhesus monkeys. Treatment should be discontinued if a woman becomes pregnant, or plans to become pregnant during therapy. Not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to E. coli-derived products, natural or recombinant interferon beta, human albumin or any other component of the formulation.
Warnings and precautions
Anaphylaxis reported (rarely). Associated with a high incidence of flu-like adverse effects. Hepatotoxicity reported with beta interferons (use with caution in hepatic impairment). Increased risk of infection. Severe injection site reactions (necrosis) might occur. Interferons associated with severe psychiatric adverse events (psychosis, mania, depression, suicidal behavior/ideation) in patients with and without previous psychiatric symptoms; avoid use in severe psychiatric disorders and use caution in history of depression; patients exhibiting symptoms of depression should be closely monitored and discontinuation of therapy should be considered. Use with caution in the following cases: bone marrow suppression, pre-existing cardiovascular disease, respiratory disease, renal impairment, or history of seizure disorder. Contains albumin (remote risk of transmitting Creutzfeldt-Jakob or other viral diseases).